Tocilizumab in COVID-19: some clarity amid controversy. | Lancet;397(10285): 1599-1601, 2021 05 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Tocilizumab in COVID-19: some clarity amid controversy.

Gupta, Shruti; Leaf, David E.

Gupta S; Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sgupta21@bwh.harvard.edu.
Leaf DE; Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA, USA.

Lancet ; 397(10285): 1599-1601, 2021 05 01.

Article in English | MEDLINE | ID: covidwho-1301059

Subject(s)

COVID-19 Drug Treatment; Antibodies, Monoclonal, Humanized; Hospitals; Humans; SARS-CoV-2

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Limits: Humans Language: English Journal: Lancet Year: 2021 Document Type: Article